Crestor royalty dip hits Shionogi but dolutegravir deal brightens outlook
This article was originally published in Scrip
Executive Summary
Falling global sales of Crestor (rosuvastatin) through licensee AstraZeneca have hit royalty income from the product at originator Shionogi, which fell by 5% to ¥30.7 billion ($382.3 million) in the first half ended 30 September.